Stay updated on Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.

Latest updates to the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page
- CheckyesterdayChange DetectedAdded navigation/help sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', and updated the 'Intervention/Treatment' heading (replacing the older 'Intervention / Treatment'). The changes also include the addition 'No longer looking for participants' and revision tag updated to v3.6.0.SummaryDifference0.3%

- Check8 days agoChange DetectedThe page's revision tag was updated from v3.5.4 to v3.5.5, signaling a small system or content update. This change does not modify study details or other user-visible content.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing the previous v3.5.3.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page footer now shows an updated site revision number (from v3.5.2 to v3.5.3), indicating a new release of the ClinicalTrials.gov interface without altering the study information presented.SummaryDifference0.0%

- Check58 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check73 days agoChange DetectedThe Publications section was updated to include the 2024 Blood article by Friedberg et al. on frontline brentuximab vedotin therapy for older HL patients ineligible for chemotherapy, and the Erratum for that Blood article was removed.SummaryDifference0.0%

Stay in the know with updates to Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.